Nasdaq12d
Can-Fite BioPharma Announces FDA Approval for Compassionate Use of Namodenoson in Pancreatic Cancer Patient
Can-Fite BioPharma Ltd. has announced FDA approval for compassionate use of its anti-cancer drug Namodenoson for a U.S. pancreatic cancer patient. This approval allows the physician to provide the ...
Can-Fite Initiates Pivotal Phase 3 Psoriasis Study of its Oral Drug Piclidenoson with FDA & EMA-Approved Protocol
The psoriasis market is estimated at $30 Billion by 2030 and has shifted significantly to oral drugsRamat Gan, Israel, March 24, 2025 (GLOBE ...
Yahoo Finance11d
Can-Fite to Initiate Phase II Study in the Rare Genetic Disease Lowe Syndrome with Piclidenoson
Ramat Gan, Israel, March 19, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CANF), a ...
Nasdaq10d
Can-Fite BioPharma Projects $325 Million in Revenue from Piclidenoson Under Veterinary Partnership with Vetbiolix
Can-Fite BioPharma Ltd. announced that its veterinary partner, Vetbiolix, is starting advanced clinical trials using the drug Piclidenoson to treat dogs with osteoarthritis, following a successful ...